Uptake Medical Announces First Patients Treated in Clinical Trial for Patients with Heterogeneous Emphysema (the VAPOR trial)
Posted Jan 05 2010 10:33am
BTVA Animation >>
Uptake Medical Corp., a developer of medical technologies for the non-surgical treatment of lung diseases including emphysema, announced today that the first patients were treated in its Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction in Patients Diagnosed with Heterogeneous Emphysema with Upper Lobe Predominance (VAPOR) trial.
The successful treatment of the first two patients in the VAPOR trial occurred on December 17th, 2009 at the Alfred Hospital in Melbourne, Australia. The procedure was performed by Dr. Gregory Snell, Dr. Trevor Williams and the Alfred Hospital team and attended by Founder and CTO Robert Barry. “We continue to be impressed not only with the ease and simplicity of the procedure, but the excellence of the sites participating in this study. The Alfred team continues to lead the way in clinical studies aimed at helping emphysema sufferers,” Barry said.
The VAPOR trial is a multi-national study designed to collect data to support CE Mark approval. It is being conducted at sites in Australia and Europe.